Cronos Reports FY25 Net Revenue of $146.6M
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 4 days ago
0mins
Should l Buy CRON?
Reports FY25 net revenue $146.6M vs, $117.6M last year. Cronos delivered record net revenue, gross profit and Adjusted EBITDA in 2025, reflecting the continued strength of our core business and the progress we are making towards our strategic priorities. We achieved record net revenue for both the fourth quarter and the full year, driven by strong consumer demand for our leading brands, the completion of the expansion at Cronos GrowCo, and the increasing contribution from our international markets," said Mike Gorenstein, Chairman, President and CEO of Cronos. Looking ahead, we are excited about the opportunities in front of us as we enter 2026," continued Gorenstein. "Once completed, our pending acquisition of CanAdelaar will establish a strategic footprint in Europe and enable us to leverage our borderless product strategy in the Netherlands' legal adult-use cannabis market. Outside the Netherlands, with the scale benefits expected from Cronos GrowCo's expansion, continued growth in our proprietary products, and the strength of our international presence, we believe Cronos is well-positioned to deliver sustainable net revenue and Adjusted EBITDA growth and to create long-term shareholder value."
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CRON?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CRON
Wall Street analysts forecast CRON stock price to rise
2 Analyst Rating
1 Buy
1 Hold
0 Sell
Moderate Buy
Current: 2.670
Low
2.30
Averages
2.72
High
3.14
Current: 2.670
Low
2.30
Averages
2.72
High
3.14
About CRON
Cronos Group Inc. is a global cannabinoid company engaged in building disruptive intellectual property by advancing cannabis research, technology and product development. The Company’s diverse international brand portfolio includes Spinach, PEACE NATURALS and Lord Jones. Spinach is a mainstream adult-use cannabis brand with a portfolio that includes cannabinoid products in a wide range of formats, including dried flower, pre-rolls, vaporizers, edibles and tinctures. Lord Jones is a premium adult-use cannabis brand. The Lord Jones brand portfolio includes cannabis products in the pre-roll, vaporizer and edible categories. Lord Jones Ice Water Hash Fusions pre-rolls feature flower and terpene-rich ice water hash and are fitted with a branded ceramic tip. PEACE NATURALS is a global medical brand engaged in producing cannabis products. The Company distributes products under the PEACE NATURALS brand for the Canadian market and the Israeli, German, and United Kingdom medical markets.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cronos Group Reports Record Growth in 2025 Earnings Call
- Significant Revenue Growth: Cronos Group reported a consolidated net revenue of $44.5 million for Q4 2025, reflecting a 47% year-over-year increase driven by strong cannabis flower sales in Israel and Canada, underscoring the continued strength of its core business.
- Market Leadership Reinforced: The Spinach brand emerged as the second-largest vape brand in Canada and achieved the top market share in vape cartridges, further solidifying the company's leadership position in the rapidly growing consumer goods market.
- Strategic Acquisition Plans: The company announced a definitive agreement to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for €57.5 million (approximately $67.5 million), with closing expected in H1 2026, which will provide robust support for the company's expansion into the European market.
- Strong Financial Position: Cronos Group maintains the strongest balance sheet in the industry with no debt and $832 million in cash and short-term investments, demonstrating the company's financial flexibility for future expansions and acquisitions.
See More
Cronos Reports Q4 Revenue Beat Despite Net Loss
- Significant Revenue Growth: Cronos reported $44.5 million in revenue for Q4 2025, reflecting approximately 47% year-over-year growth, exceeding market expectations by $5.8 million, primarily driven by improved flower sales in multiple countries, including Israel.
- Gross Profit Increase: The company's gross profit rose nearly 50% year-over-year to $16.2 million, indicating enhanced sales volumes and average selling prices, although overall performance was impacted by foreign currency transaction losses.
- Net Loss Reported: Despite revenue growth, Cronos swung to a net loss of $0.5 million from a net income of $43.9 million in the prior-year period, highlighting the significant impact of foreign exchange losses on the company's financials.
- Annual Financial Overview: For the full year, Cronos posted a net loss of $9.4 million on $146.6 million in revenue, indicating approximately 25% year-over-year growth, while cash and cash equivalents fell about 8% year-over-year to $791.8 million, reflecting financial pressures amid market expansion efforts.
See More
Cronos Group Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Cronos Group reported a Q4 GAAP EPS of $0.00, missing expectations by $0.02; however, revenue reached $44.53 million, reflecting a 47% year-over-year increase and exceeding market expectations by $5.78 million, indicating strong revenue growth.
- Adjusted EBITDA Improvement: The adjusted EBITDA for Q4 was $0.5 million, improving by $7.7 million from Q4 2024, primarily driven by higher adjusted gross profit, showcasing significant progress in cost control and profitability.
- Geographic Expansion Strategy: Supported by a strong balance sheet, Cronos Group is actively pursuing geographic expansion to enhance market share and brand influence, particularly in the rapidly growing legal cannabis market.
- Competitive Advantage: Cronos Group boasts a standout balance sheet compared to its peers, strengthening its competitive position in the industry and providing a relatively safe investment option amid future market fluctuations.
See More
Cronos Group Reports Fourth Quarter Loss
- Quarterly Loss: Cronos Group reported a swing to a loss in the fourth quarter, indicating pressure from market competition that may undermine investor confidence.
- Stock Price Decline: The stock fell 4% in U.S. pre-market trading, reflecting negative market sentiment regarding its financial performance, which could lead to short-term capital outflows.
- Market Environment Challenges: The company faces intense industry competition and regulatory pressures, impacting its profitability and creating uncertainty around future growth prospects.
- Investor Attention: Investors should closely monitor the company's strategic adjustments and market responses to assess its long-term investment value and potential returns.
See More
Cronos Group Reports Record Revenue in 2025 Financial Results
- Revenue Growth: In Q4 2025, net revenue reached $44.5 million, a 47% year-over-year increase, while full-year revenue was $146.6 million, up 25%, reflecting strong consumer demand and positive market expansion impacts.
- Gross Margin Improvement: Q4 2025 gross profit was $16.2 million, a 50% increase year-over-year, with full-year gross profit at $62.8 million, up 149%, primarily driven by higher sales prices and volumes in Israel and other countries.
- International Market Expansion: Cronos GrowCo significantly contributed $10.3 million in flower sales for the full year 2025, enhancing the company's growth in international markets, particularly with sustained market share increases in Israel.
- Strategic Acquisition Plans: The company plans to acquire CanAdelaar for $67.5 million, further solidifying its market position in Europe and expected to enhance its competitiveness in the Netherlands' legal adult-use cannabis market.
See More
Cronos Group to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Cronos Group is set to release its Q4 earnings on February 26 before the market opens, with consensus EPS estimates at $0.02 and revenue expectations of $38.75 million, reflecting a robust 27.9% year-over-year growth that indicates strong recovery potential in the market.
- Financial Health: The company boasts a standout balance sheet among its peers, providing solid financial backing for its geographic expansion strategy, which is expected to further enhance its competitive position in the cannabis industry.
- Market Expectation Analysis: As discussions around cannabis rescheduling gain momentum, Cronos is viewed as a safer investment option, attracting investor interest that may be reflected in its upcoming earnings report, showcasing its advantageous market positioning.
- Historical Performance Review: Historical earnings data indicates that Cronos Group has maintained stable performance, boosting investor confidence in its future growth, particularly amid the rapid changes in the cannabis sector.
See More
Cronos Group Reports Record Growth in 2025 Earnings Call
- Significant Revenue Growth: Cronos Group reported a consolidated net revenue of $44.5 million for Q4 2025, reflecting a 47% year-over-year increase driven by strong cannabis flower sales in Israel and Canada, underscoring the continued strength of its core business.
- Market Leadership Reinforced: The Spinach brand emerged as the second-largest vape brand in Canada and achieved the top market share in vape cartridges, further solidifying the company's leadership position in the rapidly growing consumer goods market.
- Strategic Acquisition Plans: The company announced a definitive agreement to acquire CanAdelaar, the largest operator in the Netherlands' legal adult-use cannabis program, for €57.5 million (approximately $67.5 million), with closing expected in H1 2026, which will provide robust support for the company's expansion into the European market.
- Strong Financial Position: Cronos Group maintains the strongest balance sheet in the industry with no debt and $832 million in cash and short-term investments, demonstrating the company's financial flexibility for future expansions and acquisitions.
See More
Cronos Reports Q4 Revenue Beat Despite Net Loss
- Significant Revenue Growth: Cronos reported $44.5 million in revenue for Q4 2025, reflecting approximately 47% year-over-year growth, exceeding market expectations by $5.8 million, primarily driven by improved flower sales in multiple countries, including Israel.
- Gross Profit Increase: The company's gross profit rose nearly 50% year-over-year to $16.2 million, indicating enhanced sales volumes and average selling prices, although overall performance was impacted by foreign currency transaction losses.
- Net Loss Reported: Despite revenue growth, Cronos swung to a net loss of $0.5 million from a net income of $43.9 million in the prior-year period, highlighting the significant impact of foreign exchange losses on the company's financials.
- Annual Financial Overview: For the full year, Cronos posted a net loss of $9.4 million on $146.6 million in revenue, indicating approximately 25% year-over-year growth, while cash and cash equivalents fell about 8% year-over-year to $791.8 million, reflecting financial pressures amid market expansion efforts.
See More
Cronos Group Q4 Earnings Beat Expectations with Strong Revenue Growth
- Earnings Highlights: Cronos Group reported a Q4 GAAP EPS of $0.00, missing expectations by $0.02; however, revenue reached $44.53 million, reflecting a 47% year-over-year increase and exceeding market expectations by $5.78 million, indicating strong revenue growth.
- Adjusted EBITDA Improvement: The adjusted EBITDA for Q4 was $0.5 million, improving by $7.7 million from Q4 2024, primarily driven by higher adjusted gross profit, showcasing significant progress in cost control and profitability.
- Geographic Expansion Strategy: Supported by a strong balance sheet, Cronos Group is actively pursuing geographic expansion to enhance market share and brand influence, particularly in the rapidly growing legal cannabis market.
- Competitive Advantage: Cronos Group boasts a standout balance sheet compared to its peers, strengthening its competitive position in the industry and providing a relatively safe investment option amid future market fluctuations.
See More
Cronos Group Reports Fourth Quarter Loss
- Quarterly Loss: Cronos Group reported a swing to a loss in the fourth quarter, indicating pressure from market competition that may undermine investor confidence.
- Stock Price Decline: The stock fell 4% in U.S. pre-market trading, reflecting negative market sentiment regarding its financial performance, which could lead to short-term capital outflows.
- Market Environment Challenges: The company faces intense industry competition and regulatory pressures, impacting its profitability and creating uncertainty around future growth prospects.
- Investor Attention: Investors should closely monitor the company's strategic adjustments and market responses to assess its long-term investment value and potential returns.
See More
Cronos Group Reports Record Revenue in 2025 Financial Results
- Revenue Growth: In Q4 2025, net revenue reached $44.5 million, a 47% year-over-year increase, while full-year revenue was $146.6 million, up 25%, reflecting strong consumer demand and positive market expansion impacts.
- Gross Margin Improvement: Q4 2025 gross profit was $16.2 million, a 50% increase year-over-year, with full-year gross profit at $62.8 million, up 149%, primarily driven by higher sales prices and volumes in Israel and other countries.
- International Market Expansion: Cronos GrowCo significantly contributed $10.3 million in flower sales for the full year 2025, enhancing the company's growth in international markets, particularly with sustained market share increases in Israel.
- Strategic Acquisition Plans: The company plans to acquire CanAdelaar for $67.5 million, further solidifying its market position in Europe and expected to enhance its competitiveness in the Netherlands' legal adult-use cannabis market.
See More
Cronos Group to Announce Q4 Earnings on February 26
- Earnings Announcement Schedule: Cronos Group is set to release its Q4 earnings on February 26 before the market opens, with consensus EPS estimates at $0.02 and revenue expectations of $38.75 million, reflecting a robust 27.9% year-over-year growth that indicates strong recovery potential in the market.
- Financial Health: The company boasts a standout balance sheet among its peers, providing solid financial backing for its geographic expansion strategy, which is expected to further enhance its competitive position in the cannabis industry.
- Market Expectation Analysis: As discussions around cannabis rescheduling gain momentum, Cronos is viewed as a safer investment option, attracting investor interest that may be reflected in its upcoming earnings report, showcasing its advantageous market positioning.
- Historical Performance Review: Historical earnings data indicates that Cronos Group has maintained stable performance, boosting investor confidence in its future growth, particularly amid the rapid changes in the cannabis sector.
See More
